Samambaia

This is the herb’s flagship indication and the one with the most human data. In controlled human studies, oral standardised P. leucotomos extract (PLE) raises the minimal erythema dose and blunts UV-induced erythema, sunburn-cell formation and phototoxic reactions after both natural and artificial UV, taken orally or applied topically ^{4,5Reference 4González et al. · 1997RCTTopical or oral administration with an extract of Polypodium leucotomos prevents acute sunburn and psoralen-induced phototoxic reactions — randomisedView study →Reference 5Kohli et al. · 2017Clinical trialThe impact of oral Polypodium leucotomos extract on ultraviolet B response: a human clinical studyView study →}. A human study using UVB, UVA1 and visible light found oral PLE reduced UV-induced DNA damage markers and inflammatory read-outs ^{5Reference 5Kohli et al. · 2017Clinical trialThe impact of oral Polypodium leucotomos extract on ultraviolet B response: a human clinical studyView study →}, and recent randomised placebo-controlled work in fair-skinned volunteers reported modest MED increases and reduced UVB erythema over 8 weeks ^{7Reference 7Keršmanc et al. · 2025RCTEffects of eight-week supplementation containing red orange and Polypodium leucotomos extracts on UV response — randomised double-blind placebo-controlledView study →}. Systematic reviews of oral photoprotectants consistently place PLE among the best-evidenced botanicals here, while stressing the effect is a supplement to — never a substitute for — topical sunscreen and behavioural protection ^{3Reference 3Natarelli et al. · 2025Systematic reviewOral supplements and photoprotection: a systematic reviewView study →}. Doses in these studies typically run 240–480 mg/day of standardised extract.

Gap: MED gains are real but small (roughly equivalent to a low single-digit SPF), effects are measured only for standardised extracts, and no trial shows reduced skin-cancer incidence in humans.

The antioxidant activity is the mechanistic foundation for most other claims and is well characterised in vitro. HPLC fractionation of the aqueous extract identifies a suite of phenolic acids — caffeic acid, ferulic acid, p-coumaric acid, vanillic acid, chlorogenic acid and related hydroxybenzoic/hydroxycinnamic acids — that scavenge reactive oxygen species and inhibit lipid peroxidation ^{8,9Reference 8Gombau et al. · 2006In vitroPolypodium leucotomos extract: antioxidant activity and disposition — in vitroView study →Reference 9Garcia et al. · 2006In vitroPhenolic components and antioxidant activity of Fernblock, an aqueous extract of the aerial parts of Polypodium leucotomos — in vitroView study →}. Beyond direct scavenging, the extract upregulates the NRF2 antioxidant pathway in keratinocytes, protecting them from particulate-pollution oxidative stress ^{10Reference 10Delgado-Wicke et al. · 2020In vitroFernblock upregulates NRF2 antioxidant pathway and protects keratinocytes from PM2.5-induced damage — in vitroView study →}, and inhibits both immediate and delayed (“dark”) cyclobutane pyrimidine dimer formation after UVA in cell models — a genotoxicity-relevant endpoint ^{11Reference 11Portillo-Esnaola et al. · 2021In vitroFormation of cyclobutane pyrimidine dimers after UVA exposure (dark-CPDs) is inhibited by a hydrophilic extract of Polypodium leucotomos — in vitroView study →}. Human relevance is supported indirectly by the reduced UV-induced DNA-damage markers seen in photoprotection studies ^{5Reference 5Kohli et al. · 2017Clinical trialThe impact of oral Polypodium leucotomos extract on ultraviolet B response: a human clinical studyView study →}.

Gap: The strongest data are cell-based; there is no trial measuring systemic oxidative-stress biomarkers in people taking the herb as a standalone outcome.

For idiopathic photodermatoses — chiefly polymorphic light eruption (PMLE) — oral PLE has consistent supportive human data. In an open bicenter study of 35 long-standing PLE patients, a concentrated hydrophilic extract prevented or delayed photo-induced lesions on artificial UV challenge ^{12Reference 12Tanew et al. · 2012Oral administration of a hydrophilic extract of Polypodium leucotomos for the prevention of polymorphic light eruptionView study →}. Two Italian case series (57 and 25 patients with idiopathic photodermatoses unresponsive to usual therapy) reported reduced eruptions and improved sun tolerance with oral extract ^{13,14Reference 13Caccialanza et al. · 2011Oral Polypodium leucotomos extract photoprotective activity in 57 patients with idiopathic photodermatosisView study →Reference 14Caccialanza et al. · 2007Photoprotective activity of oral Polypodium leucotomos extract in 25 patients with idiopathic photodermatosesView study →}. This is a licensed/established use of the extract in several European countries.

Gap: The supportive studies are mostly open-label and uncontrolled; there is no large double-blind placebo-controlled PMLE trial, so magnitude of benefit is uncertain.

The extract dampens several inflammatory pathways relevant to its dermatologic uses. In hairless mice, oral P. leucotomos lowered UV-induced COX-2 expression and inflammation by 48–72 hours after irradiation and enhanced DNA repair, alongside activation of the p53 tumour suppressor ^{15Reference 15Zattra et al. · 2009AnimalPolypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair in Xpc+/− mice — animal modelView study →}. In vitro, calagualine inhibits NF-κB activated by a range of inflammatory and tumour-promoting agents ^{16Reference 16Manna et al. · 2003In vitroCalagualine inhibits nuclear transcription factor-κB activated by various inflammatory and tumour-promoting agents — in vitroView study →}, and earlier work showed extract-mediated inhibition of inflammatory cytokine production and reactive oxygen intermediates. These mechanisms plausibly underpin the anti-psoriatic, photoprotective and pigmentary effects.

Gap: Human anti-inflammatory read-outs are indirect (disease-specific endpoints); there is no trial of the herb in a primary inflammatory disease with inflammatory biomarkers as the outcome.

A double-blind, placebo-controlled RCT in 40 Asian patients with melasma tested oral PLE as an add-on to topical 4% hydroquinone and SPF 50+ sunscreen over 12 weeks, reporting improved pigmentation scores in the extract arm versus placebo ^{17Reference 17Goh et al. · 2018RCTDouble-blind, placebo-controlled trial to evaluate the effectiveness of Polypodium leucotomos extract in the treatment of melasma — randomisedView study →}. A scoping review and meta-analysis of antioxidants in vitiligo and melasma ^{18Reference 18Speeckaert et al. · 2023Meta-analysisThe impact of antioxidants on vitiligo and melasma: a scoping review and meta-analysisView study →}, and a dedicated systematic review of antioxidants in melasma ^{33Reference 33Role of antioxidants in melasma: a syste · 2025Systematic reviewIndian J Dermatol. https://doi.org/10.4103/ijd.ijd_473_24View study →}, both include PLE among agents with supportive but mixed/modest evidence.

Gap: The direct RCT is small and single-centre, PLE was an adjunct (not monotherapy), and pooled effect sizes across antioxidant reviews are modest — benefit beyond good sun protection and hydroquinone is not established.

Two randomised trials test PLE as an adjunct to phototherapy. In 50 vitiligo vulgaris patients, adding oral extract to narrow-band UVB improved head-and-neck repigmentation versus placebo (44% vs 27%), though the difference was borderline (P = 0.06) and other sites were non-significant ^{19Reference 19Middelkamp-Hup et al. · 2007RCTTreatment of vitiligo vulgaris with narrow-band UVB and oral Polypodium leucotomos extract — randomised double-blind placebo-controlledView study →}. A later randomised study in 44 generalised-vitiligo patients found NB-UVB plus 480 mg PLE twice daily raised the response rate versus NB-UVB alone (47.8% vs 22%) ^{20Reference 20Pacifico et al. · 2021RCTNB-UVB plus oral Polypodium leucotomos extract display higher efficacy than NB-UVB alone in patients with vitiligo — randomised placebo-controlledView study →}. The Cochrane review of vitiligo interventions catalogues such combination approaches but rates the overall evidence base as weak ^{21Reference 21Whitton et al. · 2010Systematic reviewInterventions for vitiligo — Cochrane systematic reviewView study →}.

Gap: Benefit appears only as an adjunct to phototherapy, trials are small, one primary endpoint was borderline, and no study supports PLE monotherapy for repigmentation.

PLE has been tested as an adjunct in premalignant skin disease. A multicentre randomised open-label study in 131 elderly patients with severe actinic damage found that topical Fernblock — with or without an oral component — reduced clinical actinic keratoses and field cancerisation on confocal microscopy versus self-administered sun protection ^{22Reference 22Pellacani et al. · 2023RCTThe combination of oral and topical photoprotection with a standardized Polypodium leucotomos extract for actinic keratosis — randomised controlledView study →}. A separate RCT in 34 patients showed oral PLE added to photodynamic therapy improved scalp AK outcomes ^{23Reference 23Auriemma et al. · 2015RCTPolypodium leucotomos supplementation in the treatment of scalp actinic keratosis — randomised controlledView study →}, and a comparative RCT evaluated oral PLE against colchicine cream and ingenol mebutate ^{25Reference 25Miola et al. · 2023RCTEfficacy of oral Polypodium leucotomos, colchicine cream and ingenol mebutate in the treatment of actinic keratosis — randomised controlledView study →}. Recent systematic reviews of dietary supplements for AK include PLE among candidates with preliminary support ^{24Reference 24Rodríguez-Luna et al. · 2025Systematic reviewSystematic review on dietary supplements in the prevention and/or treatment of actinic keratosisView study →}.

Gap: All human data are adjunctive and short-term; there is no evidence that PLE alone clears AK or prevents progression to squamous cell carcinoma.

Chronic photoaging endpoints are supported mainly by cell and biophysical data. In UV-exposed fibroblasts and keratinocytes, P. leucotomos preserved membrane integrity, reduced lipid peroxidation and beneficially regulated matrix metalloproteinase-1, elastin and fibrillar collagen — the extracellular-matrix changes that drive skin ageing ^{26,27Reference 26Philips et al. · 2003In vitroPredominant effects of Polypodium leucotomos on membrane integrity, lipid peroxidation, and expression of elastin and matrix metalloproteinase-1 in UV-exposed fibroblasts and keratinocytes — in vitroView study →Reference 27Philips et al. · 2009In vitroBeneficial regulation of matrix metalloproteinases and their inhibitors, fibrillar collagens and TGF-β by Polypodium leucotomos — in vitroView study →}. The extract also protected dermal cells against visible and infrared-A radiation, which contribute to hyperpigmentation and MMP induction ^{28Reference 28Zamarrón et al. · 2018In vitroFernblock prevents dermal cell damage induced by visible and infrared-A radiation — in vitroView study →}. Some human combination-supplement trials report improved skin biophysical parameters, but these test multi-ingredient formulas.

Gap: The core mechanistic data are in vitro; human anti-photoaging outcomes come from combination products, so the isolated contribution of the herb is unclear.

One phase IV randomised, double-blind, placebo-controlled multicentre trial in 105 children and adolescents (ages 2–17) with moderate atopic dermatitis tested oral PLE added to standard topical corticosteroids over 6 months, examining whether it reduced corticosteroid use and disease severity ^{29Reference 29Ramírez-Bosca et al. · 2012RCTPolypodium leucotomos extract in atopic dermatitis: a randomised, double-blind, placebo-controlled trialView study →}.

Gap: This is a single trial in one population; the finding needs independent replication before atopic dermatitis can be considered an evidence-backed use.

The anticancer narrative rests almost entirely on mechanism, not clinical outcomes. Calagualine inhibits NF-κB — a transcription factor whose constitutive activation blocks apoptosis, promotes proliferation and drives chemoresistance — across multiple cell lines in vitro ^{16Reference 16Manna et al. · 2003In vitroCalagualine inhibits nuclear transcription factor-κB activated by various inflammatory and tumour-promoting agents — in vitroView study →}. In animal models, oral extract blocked UVB-induced skin tumour formation, reduced COX-2 and activated p53 ^{15Reference 15Zattra et al. · 2009AnimalPolypodium leucotomos extract decreases UV-induced Cox-2 expression and inflammation, enhances DNA repair in Xpc+/− mice — animal modelView study →}. These are the same pathways behind its anti-inflammatory and photoprotective effects, and they support a plausible chemopreventive rationale in the skin.

Gap: There are no human oncology trials and no clinical outcome data; describing samambaia as a cancer “treatment” overstates cell-line and rodent findings.

Interest here began with incidental reports of cognitive improvement in psoriasis patients taking Anapsos, followed by a small double-blind randomised placebo-controlled pilot in 45 patients with mild-to-moderate senile dementia (vascular and Alzheimer type), which examined effects on cognition, brain bioelectrical activity and cerebral hemodynamics ^{30Reference 30Álvarez et al. · 2000RCTDouble-blind, randomised, placebo-controlled pilot study with anapsos in senile dementia — randomisedView study →}. Mechanistic support comes from a rat study in which anapsos modulated Cu-Zn superoxide dismutase activity in a beta-amyloid model of neuronal degeneration ^{31Reference 31Fernández-Novoa et al. · 1997AnimalEffects of anapsos on Cu-Zn-superoxide dismutase activity in an animal model of neuronal degeneration — animalView study →}.

Gap: The human evidence is a single small pilot from 2000 that has not been replicated; the claim of established dementia benefit is not supported, and the neuro preparation differs from modern dermatologic extracts.

Antiviral activity rests on a single early screen: an extract of P. leucotomos showed inhibitory activity against herpes simplex virus type 1 in an in-vitro survey of British Columbian and other medicinal plants ^{32Reference 32McCutcheon et al. · 1995In vitroAntiviral screening of British Columbian medicinal plants — in vitroView study →}.

Gap: One in-vitro screen with no follow-up and no whole-organism or human data — essentially a preliminary signal only.

Standardised Polypodium leucotomos extract has a favourable safety record in clinical use: a review of trials spanning over 40 years and daily doses from 120 to 1,080 mg found no serious adverse effects, with only occasional mild gastrointestinal upset and, rarely, pruritus reported ^{1Reference 1Winkelmann et al. · 2015ReviewPolypodium leucotomos extract: a status report on clinical efficacy and safety — reviewView study →}. A dedicated safety study in healthy adults taking the extract twice daily for 60 days recorded no clinically meaningful changes in physical examination, vital signs or laboratory panels (haematology, metabolic panel, coagulation) ^{6Reference 6Nestor et al. · 2015RCTSafety and efficacy of oral Polypodium leucotomos extract in healthy adult subjects — randomised placebo-controlledView study →}. Reliable, well-documented drug-interaction data are limited; older secondary sources caution about potentiation of cardiac glycosides (digitalis/digoxin) and reduced absorption with antacids, but these claims are not supported by primary pharmacokinetic studies and should be treated as theoretical. Almost all safety data concern proprietary standardised extracts rather than raw fern powder or home preparations, so the safety of whole-herb tea or powder is essentially unstudied.